Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MOLN
stocks logo

MOLN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.280
-6.67%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Molecular Partners AG (MOLN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 26.12%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+26.12%
In Past 3 Month
Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 8.33 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 8.33 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.515
sliders
Low
4.00
Averages
8.33
High
12.00
Current: 4.515
sliders
Low
4.00
Averages
8.33
High
12.00
JPMorgan
Richard Vosser
Neutral
downgrade
$4
2025-09-03
Reason
JPMorgan
Richard Vosser
Price Target
$4
2025-09-03
downgrade
Neutral
Reason
JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $4 from $4.50 and keeps a Neutral rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Molecular Partners AG (MOLN.O) is -3.29, compared to its 5-year average forward P/E of -3.02. For a more detailed relative valuation and DCF analysis to assess Molecular Partners AG 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.02
Current PE
-3.29
Overvalued PE
2.18
Undervalued PE
-8.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
2.98
Current EV/EBITDA
-0.68
Overvalued EV/EBITDA
35.68
Undervalued EV/EBITDA
-29.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
29.25
Current PS
0.00
Overvalued PS
72.01
Undervalued PS
-13.51
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MOLN News & Events

Events Timeline

(ET)
2025-11-12
05:45:26
Molecular Partners unveils new data on MP0712
select
2025-08-21 (ET)
2025-08-21
05:11:45
Molecular Partners names Martin Steegmaier as its new chief scientific officer.
select
2025-06-11 (ET)
2025-06-11
16:03:53
Molecular Partners to preent updated data from MP0533 trial at EHA congress
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-03Yahoo Finance
Molecular Partners to Showcase New Data from Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

  • Clinical Trial Announcement: Molecular Partners AG will present updated data from a Phase 1/2a trial of MP0533, a T cell engager for acute myeloid leukemia (AML), at the 67th ASH Annual Meeting in December 2025, highlighting its safety profile and preliminary antitumor activity.

  • Mechanism of Action: MP0533 is a tetra-specific DARPin that targets multiple antigens on AML cells while engaging T cells, designed to enhance T cell-mediated killing of cancer cells while minimizing damage to healthy cells.

  • DARPin Therapeutics Overview: DARPins are a new class of protein drugs that offer high specificity and multi-target capabilities, providing advantages in drug design over traditional protein-based therapeutics.

  • Company Background: Molecular Partners AG, founded in 2004, focuses on developing DARPin therapeutics for oncology and other medical challenges, leveraging partnerships and proprietary programs to deliver innovative solutions.

[object Object]
Preview
4.0
09-03Benzinga
JP Morgan Keeps Neutral Rating on Molecular Partners, Reduces Price Target to $4

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
2.0
08-26Benzinga
EHang, Molecular Partners, and Other Major Stocks Decline in Tuesday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures are down, with Dow futures decreasing by approximately 0.2% on Tuesday morning.

  • EHang Holdings Performance: EHang Holdings Ltd saw a significant drop in pre-market trading after lowering its FY2025 sales guidance from $123.299 million to $69.797 million, resulting in an 8.5% decline in share price.

  • Other Stocks Declining: Several other companies also experienced declines in pre-market trading, including Molecular Partners AG (-13.5%), Daqo New Energy Corp (-9.2%), and Harmony Gold Mining Company Ltd (-6.7%).

  • Valneva SE Update: Valneva SE shares fell 4.6% following a 19% drop on Monday due to the FDA suspending the license for IXCHIQ.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Molecular Partners AG (MOLN) stock price today?

The current price of MOLN is 4.515 USD — it has increased 1.46 % in the last trading day.

arrow icon

What is Molecular Partners AG (MOLN)'s business?

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

arrow icon

What is the price predicton of MOLN Stock?

Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 8.33 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Molecular Partners AG (MOLN)'s revenue for the last quarter?

Molecular Partners AG revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Molecular Partners AG (MOLN)'s earnings per share (EPS) for the last quarter?

Molecular Partners AG. EPS for the last quarter amounts to -0.33 USD, decreased -32.65 % YoY.

arrow icon

What changes have occurred in the market's expectations for Molecular Partners AG (MOLN)'s fundamentals?

The market is revising No Change the revenue expectations for Molecular Partners AG (MOLN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 26.12%.
arrow icon

How many employees does Molecular Partners AG (MOLN). have?

Molecular Partners AG (MOLN) has 159 emplpoyees as of December 05 2025.

arrow icon

What is Molecular Partners AG (MOLN) market cap?

Today MOLN has the market capitalization of 168.86M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free